Sodium-glucose cotransporter 2 inhibitors across cardio-reno-metabolic disease and body mass index: a meta-analysis of randomized controlled trials.
Dimitrios Farmakis, Konstantinos I Karampinos, Chris J Kapelios et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis of randomized controlled trials evaluated the impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on cardiovascular and all-cause mortality across different body mass index (BMI) categories in patients with heart failure, chronic kidney disease, and type 2 diabetes. The study found that SGLT2i significantly reduced the risk of cardiovascular death or heart failure hospitalization in both BMI <30 kg/m2 (RR 0.80) and BMI ≥30 kg/m2 (RR 0.80), with no BMI effect modification.
Key findings
- SGLT2i reduced cardiovascular death or HF hospitalization in BMI <30 kg/m2 (RR 0.80) and BMI ≥30 kg/m2 (RR 0.80).
- Heart failure hospitalization was reduced (RR 0.75 for BMI <30 kg/m2 and 0.74 for BMI ≥30 kg/m2).
- All-cause mortality decreased (RR 0.83 for BMI <30 kg/m2 and 0.89 for BMI ≥30 kg/m2).
- No evidence of BMI interaction affecting SGLT2i benefits was found.
Why it matters
Understanding the effectiveness of SGLT2 inhibitors across different BMI categories is crucial for optimizing treatment strategies in patients with cardio-reno-metabolic diseases, ensuring that all patients can benefit from these therapies regardless of their weight status.